Key Highlights

  • TVTX's total Revenue for the third quarter of 2026 amounted to $224.6 million, improving on $164.9 million in the same span a year prior.
  • FILSPARI generated $200.2 million in net sales, more than double the $90.9 million booked a year earlier.
  • Results moved to a net Deficit of $52.3 million, which equals $0.55 a share, versus Net Income of $25.7 million, equal to $0.28 a share, a year prior.
  • A $113.1 million expense for in-process work tied to the civorebrutinib license weighed on the period.
  • Sep 30, 2026 balances showed $123.5 million in cash and equivalents, with an added $348.3 million in marketable Debt securities.

FILSPARI Revenue Passes the $200 Million Mark Across IgA Nephropathy and FSGS

Travere Therapeutics (NASDAQ:TVTX) closed its third quarter, which ended Sep 30, 2026, and results came out on Nov 2, 2026. Revenue for the period came to $224.6 million, a 36.2% rise (calculated) against $164.9 million one year before. Net product sales accounted for $220.2 million, compared with $113.2 million a year before.

The company works on therapies for uncommon kidney and metabolic conditions. FILSPARI sales totaled $200.2 million against $90.9 million, while tiopronin sales declined to $20.0 million, down from $22.3 million.

License and collaboration income dropped to $4.4 million, since the year-ago span included a $40.0 million milestone tied to market access. Roughly 1,930 patient start forms arrived during the period across IgA nephropathy and FSGS, and pharmacy stocking orders added close to $8 million, classed as inventory-related sales.

Charge Tied to the Civorebrutinib Deal Drives a $52.3 Million Quarterly Loss

Operating results moved to a $68.1 million loss from $24.9 million of Operating Income the year before. Within that result sits a $113.1 million in-process expense tied to the civorebrutinib license, with $112.5 million representing an upfront payment.

Research and development outlays increased to $70.3 million, up from $51.9 million, reflecting pegtibatinase trial enrollment and Manufacturing work. Selling, general and administrative spending climbed to $98.4 million, against $71.0 million a year earlier, because the sales force expanded before the FSGS introduction.

Continuing operations produced a $61.0 million loss, or $0.64 a share. Discontinued operations contributed $8.7 million, leaving the net result at negative $52.3 million, equal to $0.55 for each diluted share, against $25.7 million, or $0.28, last year.

Convertible Notes Lift Debt While Nine-Month Operating Cash Turns Positive

At Sep 30, 2026, the company's cash stood at $123.5 million, while marketable debt securities totaled $348.3 million. Convertible obligations rose to $603.5 million, up from $311.7 million on Dec 31, 2025, after new 2032 notes were issued and some 2029 notes were bought back. The repurchase generated a $40.0 million inducement charge during the second quarter.

Nine-month operating cash generation from continuing operations reached $92.4 million, a swing from $22.9 million of cash used a year prior. Revenue for the nine months totaled $521.3 million compared with $361.0 million.

CEO Transition and 2027 Pipeline Readouts Shape the Coming Quarters

The chief executive intends to leave in December, and a replacement is set to start on Dec 1, 2026. Leadership reaffirmed its aim of surpassing $3 billion in yearly FILSPARI sales by 2033, and anticipates that roughly $8 million of sales in the final quarter will be counterbalanced as pharmacy inventories return to normal.

Top-line data from the pegtibatinase Phase 3 study are slated for the second half of 2027. A filing for civorebrutinib with U.S. regulators, based on an investigational new drug, is planned for the current quarter.